Synairgen is a University spin-off and public limited company (plc) [2][1][3] working in drug discovery and biotechnology.
[10] Synairgen has developed and is testing an inhaled formulation of interferon beta, a naturally occurring protein which orchestrates the body's antiviral responses.
[12] In March 2020,[13] Synairgen initiated a placebo-controlled Phase 2 trial of SNG001, an inhaled form of interferon beta, in COVID-19 patients in the UK.
[14] The Phase 3 SPRINTER trial (SG018), a randomised, double-blind, placebo-controlled study evaluating SNG001 for the treatment of hospitalised COVID-19 patients, was initiated in January 2021.
The ACTIV-2 study, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and led by the NIAID-funded AIDS Clinical Trials Group (ACTG), is testing agents in outpatient adults with documented positive SARS-CoV-2 infection and symptoms of COVID-19.